Single-cell transcriptomic prioritization of SQLE and functional validation of SQLE inhibition in colorectal cancer cells
This study identifies SQLE as a key candidate gene within downregulated lipid/cholesterol metabolic programs associated with treatment-induced epithelial cell-state changes in colorectal cancer, demonstrating that its inhibition via terbinafine suppresses tumor cell viability and proliferation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Colorectal cancer is a disease where cells in the lining of the large intestine grow out of control. When doctors treat this cancer, they often use powerful drugs to kill the tumor, but the response varies wildly; some tumors shrink dramatically while others barely change. To understand why, scientists have begun looking at tumors not just as a single mass, but as a bustling city made of many different types of cells. Inside this city, there are cancer cells, immune cells, and structural cells, all talking to one another. A major challenge in studying these tumors has been that traditional methods mix all these cells together, blurring the specific changes happening inside the cancer cells themselves. Recently, a new technology has allowed researchers to look at individual cells one by one, revealing how their internal instructions change when they face the pressure of treatment. One of the most critical instructions inside a cell involves how it manages its energy and building blocks, specifically how it makes fats and cholesterol. These molecules are essential for the cell to grow, divide, and build new membranes. If a cancer cell is forced to slow down its growth because of treatment, it might also shut down the factories that produce these fats. Understanding this connection could reveal new ways to stop the cancer from surviving or regrowing.
A team of researchers set out to explore this exact question: how do the instructions inside colorectal cancer cells change after they are treated, and does this involve the way the cells handle fats and cholesterol? They started by examining two large collections of data from patients who had received treatment for colorectal cancer. Using a method that reads the genetic activity of thousands of individual cells, they compared the cancer cells before treatment to the same cells after treatment. They found that the treatment did not just kill off some cells; it fundamentally reshaped the state of the surviving cancer cells. The cells that remained after treatment had shifted their internal programs. Specifically, the researchers noticed a consistent pattern where the genes responsible for making cholesterol and other fats were turned down significantly. It was as if the surviving cancer cells had decided to conserve energy and stop building new structures, likely as a way to endure the stress of the chemotherapy.
To figure out which specific genes were most important in this fat-making shutdown, the researchers looked for the genes that appeared to be turning down in both of their patient groups. They found a small group of five genes that were consistently less active after treatment. These genes act like a team of workers in a factory, each responsible for a different step in the process of building cholesterol. Among these five, one gene stood out as a particularly strong candidate for further study. This gene, known as SQLE, provides the instructions for an enzyme that acts as a crucial gatekeeper in the cholesterol-making pathway. The researchers checked this finding against other large databases of patient information. They discovered that in tumors that responded well to chemotherapy, this SQLE gene was actually more active than in tumors that did not respond. Furthermore, when they looked at tumors from patients who had passed away, those with higher levels of this gene tended to have a poorer outlook. This suggested that while the gene might be turned down by treatment as a survival tactic, having high levels of it in the first place is linked to more aggressive disease.
To test whether stopping this gene could actually hurt the cancer cells, the researchers moved from computer analysis to a laboratory setting. They grew human colorectal cancer cells in a dish and treated them with a drug called terbinafine. This drug is already known to block the activity of the SQLE enzyme. The results were clear: when the researchers added the drug, the cancer cells began to struggle. They grew more slowly, and fewer of them were actively copying their DNA, which is a sign that they had stopped dividing. In a test that measured the ability of a single cell to grow into a large colony over time, the treated cells formed far fewer colonies than the untreated ones. The drug essentially starved the cells of their ability to keep up the rapid growth that defines cancer.
The study concludes that the way colorectal cancer cells handle cholesterol is a key part of how they react to treatment. When these cells face the pressure of chemotherapy, they tend to dial back their fat-making machinery, and the gene SQLE is a central player in this process. While the researchers found that blocking this gene with a drug can slow down cancer cell growth in a dish, they are careful to note that this is a preliminary step. The experiments showed a clear trend and a biological possibility, but they did not yet prove that this approach would work as a cure in people. The findings suggest that targeting the cholesterol-making pathway could be a promising strategy, but more work is needed to understand exactly how this gene drives the disease and whether blocking it can safely help patients in the long run. The research highlights that by looking at the specific metabolic shifts inside individual cancer cells, scientists can uncover new vulnerabilities that might be exploited to improve treatment outcomes.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.